Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Jan 1;12(3):1061–1073. doi: 10.7150/thno.65299

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The author(s)

This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions.

PMC Copyright notice

Enhanced efficacy, cellular deposition efficiency, and tumor growth inhibition of DEX-TP towards KRAS mutant cancer. (A and B) Chemical structures of TP (A) and DEX-TP (B). (C and D) Drug efficacy of DEX-TP (C) and TP (D) towards BxPC-3 (CTRL) and BxPC-3 KRAS^G12V (KRAS^G12V) cells. Error bars indicate the mean and SD, n=3. (E) Cellular deposition efficiency of DEX-TP under different KRAS gene backgrounds. (F, G and H) Tumor growth curves (left) and body weight surveillance (right) under the following drug treatments: MIA PaCa-2-derived subcutaneous model (F), n (saline) = 7, n (TP) = 8, n (DEX-TP) = 8, and error bars indicate the mean and SD; BxPC-3 derived subcutaneous model (G), n (saline) = 4, n (TP) = 6, n (DEX-TP) = 6, and error bars indicate the mean and SD; BxPC-3 KRAS^G12V-derived subcutaneous mode (H), n (saline) = 7, n (TP) = 7, n (DEX-TP) = 7, and error bars indicate the mean and SD. All treatments were given every two days for a total of 7 treatments via tail vein injection, and doses are denoted as TP equivalents.